Targeting the interferon-pathway in idiopathic inflammatory myopathies: a multicentre, 26-week, open-label phase 2 trial of the JAK inhibitor filgotinib

Rituxan (rituximab) - Roche

Jyseleca (filgotinib) - Gilead

https://ewrr.eular.org/programme/presentation/23329

Bettina Geertsema-Hoeve1; Merve Kocyigit2; César Magro Checa3; Jan van Laar4; Sander Tas5; Paco Welsing6; Robbert Goekoop7; R.M. Thurlings8; Nicolle Rekers9; Erik Present9; Joost Raaphorst10; Jacob M. van Laar1

May 5, 2026